S&P Equity Research downgrades PDL BioPharma Inc. (Nasdaq: PDLI) from Buy to Hold.

S&P analyst, S. Sliver, says, "After ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE